Citius Oncology, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTOR research report →
Companywww.citiusonc.com/overview/default.aspx
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma.
- CEO
- Leonard L. Mazur
- IPO
- 2022
- Employees
- 285
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $76.80M
- P/E
- -1.94
- P/S
- 13.69
- P/B
- 2.34
- EV/EBITDA
- -1.82
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 80.07%
- Op Margin
- -775.60%
- Net Margin
- -757.57%
- ROE
- -99.47%
- ROIC
- -103.90%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-24,761,369 · -17.08%
- EPS
- $-0.34 · -13.33%
- Op Income
- $-23,522,750
- FCF YoY
- -4446.73%
Performance & Tape
- 52W High
- $6.19
- 52W Low
- $0.49
- 50D MA
- $0.80
- 200D MA
- $1.29
- Beta
- 3.58
- Avg Volume
- 237.63K
Get TickerSpark's AI analysis on CTOR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 19, 25 | HOLUBIAK MYRON Z | other | 850,000 |
| Sep 19, 25 | HOLUBIAK MYRON Z | other | 100,000 |
| Sep 19, 25 | Smith Robert Joseph | other | 300,000 |
| Sep 19, 25 | Mazur Leonard L | other | 1,700,000 |
| Sep 19, 25 | Webb Carol | other | 300,000 |
| Sep 19, 25 | Czuczman Myron | other | 825,000 |
| Sep 19, 25 | MCGRATH DENNIS M | other | 300,000 |
| Sep 19, 25 | Bartushak Jaime | other | 825,000 |
| Sep 19, 25 | Mayersohn Joel David | other | 300,000 |
| Sep 19, 25 | Dutia Suren G | other | 300,000 |
Our CTOR Coverage
We haven't published any research on CTOR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CTOR Report →